Combination Chemotherapy with Bortezomib, Cyclophosphamide and Dexamethasone may be Effective for Plasma Cell Leukemia
Open Access
- 1 May 2007
- journal article
- case report
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 37 (5), 382-384
- https://doi.org/10.1093/jjco/hym037
Abstract
Plasma cell leukemia is a rare malignant plasma cell disorder characterized by proliferation of plasma cells in blood and the bone marrow, the outcome of which is poor with conventional therapy. More effective treatment strategies are therefore needed for this disorder. Here, we report a case of secondary plasma cell leukemia from Immunoglobulin D multiple myeloma refractory to doxorubicin-containing chemotherapy and thalidomide. The patient achieved complete remission with bortezomib-containing chemotherapy as follows: bortezomib 1.3 mg/m2 intravenous infusion on days 1, 4, 8 and 11; cyclophosphamide 750 mg/m2 intravenous infusion on days 1 and 3; dexamethasone 40 mg/m2 intravenous infusion on days 1–4. Complete remission was maintained until the fourth course of the treatment, and we then performed autologous peripheral blood stem cell transplantation. Our experience suggests that combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be an effective induction treatment for plasma cell leukemia.Keywords
This publication has 12 references indexed in Scilit:
- Bortezomib is effective in primary plasma cell leukemiaLeukemia & Lymphoma, 2006
- Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myelomaLeukemia & Lymphoma, 2005
- Primary plasma cell leukemia: Report of 17 new cases treated with autologous or allogeneic stem‐cell transplantation and review of the literatureAmerican Journal of Hematology, 2005
- Approval Summary for Bortezomib for Injection in the Treatment of Multiple MyelomaClinical Cancer Research, 2004
- A Phase 2 Study of Bortezomib in Relapsed, Refractory MyelomaNew England Journal of Medicine, 2003
- Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myélome and the Groupe Français de Cytogénétique HématologiqueBlood, 2001
- NONSECRETORY MYELOMA, IMMUNOGLOBULIN D MYELOMA, AND PLASMA CELL LEUKEMIAHematology/Oncology Clinics of North America, 1999
- Primary Plasma Cell Leukemia: Clinical, Immunophenotypic, DNA Ploidy, and Cytogenetic CharacteristicsBlood, 1999
- Primary plasma cell leukaemiaBritish Journal of Haematology, 1994
- Primary Plasma Cell Leukemia: A Case Report of Successful Responder to a Combination Chemotherapy of Vincristine, Doxorubicin and DexamethasoneActa Haematologica, 1989